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Background/Purpose: High homocysteine (Hcy) concentration is associated with slow coronary flow.
This study examined the association between Hcy and hemodynamic status in the extracranial cerebral
arteries in healthy individuals.
Methods: A total of 535 healthy adults underwent physical examination and duplex ultrasonography of
the extracranial carotid and vertebral arteries, and blood laboratory tests, including biochemistry and
serum total Hcy. Flow hemodynamic parameters including velocity, resistance, and volume of the carotid
and vertebral arteries were measured. Multiple regression analysis was performed to examine the asso-
ciation between Hcy and the flow parameters.
Results: Participants with higher Hcy were more likely to have a lower systolic velocity of the internal
carotid artery (p = 0.01) and vertebral artery (p < 0.001), and lower resistance of the vertebral artery 
(p = 0.004). However, the multiple-adjusted means of the flow velocity, resistance, and flow volume of
the carotid or vertebral artery were not significantly different across quartiles of Hcy. When Hcy was
treated as a continuous variable, there was still no significant relationship between Hcy levels and the
aforementioned hemodynamic status.
Conclusion: Our results did not support the hypothesis that the levels of Hcy are associated with the flow
velocity, resistance, and volume of the extracranial cerebral artery in healthy individuals.
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Homocysteine (Hcy) is an important factor for
atherosclerosis in the large cerebral arteries.1,2
In vitro evidence exists for effects of Hcy on athero-
genesis and thrombogenesis. Experimental studies
have shown that Hcy can be harmful to vascular
smooth muscles cells and promote their prolifer-
ation. Hcy also has other possible detrimental 
effects.3–9 Besides, Hcy has been reported to be
©2010 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Department of Neurology, En Chu Kong Hospital, and 2Institute of Preventive Medicine, College of Public Health, National
Taiwan University, Taipei, Taiwan.
Received: March 3, 2009
Revised: May 31, 2009
Accepted: July 17, 2009
*Correspondence to: Dr Kuo-Liong Chien, Institute of Preventive Medicine, College of Public
Health, National Taiwan University, Taipei, Taiwan.
E-mail: klchien@ntu.edu.tw
Homocysteine and cerebral blood flow
J Formos Med Assoc | 2010 • Vol 109 • No 4 279
higher in people with slow coronary artery flow
than in those with normal flow velocity.10 Altho-
ugh the mechanisms and relationship between
Hcy and vascular hemodynamic status are not
clear, hemodynamic status of slow-flow- and low-
shear-stress-related vascular remodeling is one 
of the pathogenetic mechanisms of atherosclero-
sis.11–13 Hemodynamic data including blood flow
velocity, flow resistance, and flow volume can 
be obtained by ultrasonography.14,15 Hcy might
slow the blood flow velocity, and further induce
atherosclerosis by reducing the brain flow vol-
ume. However, studies that have investigated the
relationship between serum Hcy and cerebral he-
modynamic status have been limited in number.
To test the hypothesis that total serum Hcy is
related to cerebral slow flow, we performed a
cross-sectional study with detailed clinical evalu-
ation, serum Hcy level and duplex ultrasonogra-
phy examination on the extracranial carotid and
vertebral arteries in healthy participants.
Subjects and Methods
Participants
The study participants were invited from those pre-
senting to En Chu Kong Hospital, Taipei, Taiwan
for a physical health check-up between 1999 and
2007. We recruited 535 participants (56% male;
mean age, 55.2 ± 14.8 years), who were free from a
history of stroke, transient ischemic attack, coro-
nary heart disease, or intermittent claudication. All
participants underwent detailed questionnaires,
physical examination and clinical measurements,
including height, body weight, body mass index,
and blood pressure. Duplex ultrasonography 
of the carotid and vertebral arteries, and blood 
laboratory tests were also performed.
Ultrasound procedure and hemodynamic
measurements
Ultrasonography was performed with a Hewlett–
Packard 5500 system (Philips Electronics, Bothell,
WA, USA) equipped with a high-resolution broad-
band width linear array transducer (4–10 MHz).16
Participants were examined in the supine position.
Images were obtained bilaterally of the proximal
to distal common carotid artery (CCA), includ-
ing the bifurcation, internal carotid artery (ICA),
and external carotid artery. Images of the vertebral
artery (VA) were obtained bilaterally from the
C2–C6 segments. An experienced technologist who
was blinded to the clinical data made all the ul-
trasound measurements.
The flow parameters that we measured were the
flow velocity and resistance of the CCA, ICA and
VA.17 We also calculated the total flow volume of
the VA. With regard to the flow velocity, we mea-
sured the peak systolic, end-diastolic, time average
flow, and mean flow velocities. The following for-
mula was used to calculate the mean flow velocity:18
Mean flow velocity = (peak systolic velocity + 2
× end-diastolic velocity)/3.
As for the resistance of the vessel, indices of resis-
tance and pulsatility were measured. Resistance
index was calculated with the formula:19
Resistance index = (peak systolic velocity – 
end-diastolic velocity)/
peak systolic velocity.
Pulsatility index described the shape of the wave-
forms. The formula for calculating pulsatility index
was:20
Pulsatility index = (peak systolic velocity – 
end-diastolic velocity)/
mean flow velocity.
Pulsatility index and resistance index are believed
to be presumptive measures of downstream vas-
cular resistance.18 We measured the diameter to
calculate the flow volume of the VA. Color-coded
flow imaging was used to measure the diameter.
Flow volume was the product of flow velocity and
the area in which this velocity occurred:18
Flow volume (cm3/sec) = flow velocity (cm/sec)
× area (cm2).
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Laboratory analysis
After a 10-hour overnight, fast, blood samples were
collected to determine with standard techniques
the levels of Hcy, total cholesterol, triglycerides,
high-density lipoprotein, low-density lipoprotein,
blood glucose, hemoglobin, platelets, blood urea
nitrogen, creatinine, and uric acid. Venous blood
samples for Hcy were collected into tubes that con-
tained EDTA, transported to the laboratory
within 30 minutes after blood drawing, cen-
trifuged at 2000 rpm for 10 minutes, and stored
separately at −20°C until analysis. Serum Hcy
concentrations were measured by fluorescence
polarization immunoassay (Abbott IMx System
Abbott Lab, N. Chicago, IL, USA),21,22 which corre-
lated well with high performance liquid chroma-
tography (r value ranging from 0.980 to 0.997).23
The inter- and intraassay coefficients of variation
of Abbott IMx Analyzer were within 10%.23
Statistical analysis
Populations were categorized according to Hcy
quartiles. Continuous variables were presented
as the mean ± standard deviation or the median,
while the categorical data were presented in con-
tingency tables. All the flow parameters in the sta-
tistical analysis were the mean values from bilateral
measurements, including diameter, peak systolic
velocity, end-diastolic velocity, time average flow
velocity, mean flow velocity, resistance index,
pulsatility index, and total flow volume. Analysis 
of variance and the χ2 test were used to test the
differences of the vascular risk factors and flow
parameters between Hcy quartiles.
Multiple linear regression models were used
to examine the relationship between Hcy and the
aforementioned flow parameters. We estimated
the adjusted means of the flow parameters by ad-
justment with age and sex, and additionally, with
current smoking, systolic blood pressure, body
mass index, serum creatinine, serum uric acid, and
high-density lipoprotein. In the above analyses, we
modeled Hcy concentrations as quartiles to avoid
the assumption of linearity and to reduce the ef-
fects of outliers. To test for linear trends across Hcy
quartiles, we used median Hcy concentration for
each category in the multivariate model. In addi-
tion, to estimate the effects of Hcy, we calculated
the odds ratio (OR) and corresponding 95% con-
fidence interval (CI) for the change of flow pa-
rameters, according to one standard deviation
increase of Hcy.
All statistical tests were two-tailed and p < 0.05
was considered statistically significant. Analyses
were performed with SAS software (version 9.1;
SAS Institute).
Results
The median (interquartile range) and mean± stan-
dard deviation of Hcy for the 535 study partici-
pants were 9.1 (7.4–11.3) and 9.9 ± 4.9 μmol/L,
respectively. The median (interquartile range) of
Hcy was 7.1 (6.4–9.2) μmol/L in women com-
pared with 10.1 (8.4–12.1) μmol/L in men (p <
0.001). The ranges for Hcy quartiles were: first,
1.91–7.36μmol/L; second, 7.37–9.07μmol/L; third,
9.08–11.32μmol/L; and fourth, 11.33–58.7μmol/L.
Baseline characteristics of the study population
according to Hcy quartiles are listed in Table 1.
Higher Hcy levels were associated with older age,
current smoking, higher systolic blood pressure,
lower body mass index, higher serum creatinine,
lower total cholesterol, and higher serum uric acid.
With regard to flow parameters across Hcy quar-
tiles, participants with higher Hcy levels were more
likely to have slow systolic flow velocity in the ICA
(p = 0.01) and VA (p < 0.001), slow diastolic veloc-
ity in the CCA (p = 0.02) and ICA (p = 0.006),
and lower resistance index in the VA (p = 0.004),
as shown in Table 2. The diameter and flow vol-
ume of the VA were similar across Hcy quartiles.
The least-squares mean values of the flow pa-
rameters across quartiles of Hcy, after adjustment
for demographics and risk factors, are shown in
Table 3. There was no significant difference in the
flow velocity, resistance of the CCA, ICA, and VA,
as well as the VA flow volume between different
levels of Hcy. When Hcy was considered as a con-
tinuous variable, the Hcy levels were not related
significantly to the aforementioned hemodynamic
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status of the VA (Table 4). The results were un-
changed if we calculated the VA parameters from
the left and right side separately (data not shown).
Discussion
Our results from asymptomatic adults show that
Hcy concentrations were not associated signifi-
cantly with flow velocity and resistance of the
carotid and vertebral arteries, and the total flow
volume of the VA. To the best of our knowledge,
this study is the first to investigate the effect of
Hcy on the hemodynamic status of the extracra-
nial cerebral vessels.
Homocysteinemia plays an important role in
the risk of atherosclerosis and stenosis on the
carotid and coronary arteries.24,25 In 1041 Framing-
ham residents who had Hcy measurement and
carotid sonography, the adjusted OR for stenosis
≥25% was 2.0 (95% CI=1.4–2.9) for subjects with
Hcy levels in the highest compared with the lowest
quartile.1 In the Atherosclerosis Risk in Commu-
nities Study, subjects with thickened intima–
medial carotid walls (≥ 90th percentile) were more
likely to have elevated Hcy levels compared with
those without thickened walls (< 70th percentile).2
Several hypotheses have been proposed to ex-
plain the harmful effects of Hcy on the large ar-
teries.3–9 Some recent studies have reported the
effects of Hcy on hemodynamic status.10,26–30 The
relationship between hemodynamic status and
vascular atherosclerosis has been established.11–13
Zarins et al reported quantitative correlation of
plaque localization with flow velocity profiles and
wall shear stress.11 In previous studies of Hcy and
hemodynamic status, a significant inverse correla-
tion between Hcy and flow velocity was reported
for the coronary and ophthalmic arteries.10,29,30
High serum Hcy concentrations is associated
Table 1. Characteristics of the study population according to homocysteine quartiles
Quartiles of homocysteine*
Q1 (n = 135) Q2 (n = 133) Q3 (n = 134) Q4 (n = 133)
p
Age (yr) 50 53 56 61 < 0.001
Sex, male (%) 56 56 56 56 0.990
Hypertension (%) 21 13 25 25 0.130
Diabetes mellitus (%) 1.3 5.2 4.8 7.3 0.300
Current smoking (%) 27 38 48 55 0.008
Systolic blood pressure (mmHg) 120 124 128 132 < 0.001
Diastolic blood pressure (mmHg) 74 74 75 78 0.110
Body mass index 29 25 25 25 0.021
Laboratory biochemical 
data (mg/dL)
Fasting glucose 98 98 100 99 0.900
Serum creatinine 0.87 0.94 0.99 1.04 < 0.001
Serum uric acid 6.0 5.9 6.3 6.6 0.005
Lipid profile
Triglyceride 129 154 139 155 0.130
Total cholesterol 202 207 199 193 0.020
High-density lipoprotein 53 53 50 49 0.070
Low-density lipoprotein 133 127 122 118 0.180
*Homocysteine quartiles: Q1, 1.91–7.36mmol/L; Q2, 7.37–9.07mmol/L; Q3, 9.08–11.32mmol/L; and Q4, 11.33–58.7mmol/L.
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with the slow flow phenomenon in non-stenotic
coronary artery. Barutcu et al investigated the rela-
tionship between Hcy and the coronary slow
flow phenomenon.31 Other researchers also have
found elevated levels of plasma Hcy in patients
who have angiographically proven normal coro-
nary artery with slow flow in symptomatic10,30 and
asymptomatic28 adults. Hyperhomocysteinemia
impairs coronary flow velocity reserve in experi-
mental studies.26 The mechanisms of coronary
slow flow are still not clear. Serum Hcy-related en-
dothelial dysfunction and oxidative stress are sug-
gested to be the causes of coronary slow flow.10,26
Although there was increasing evidence of the
Hcy effect on slow flow, our study demonstrated
that there was no such association in the extracra-
nial cerebral arteries in asymptomatic adults.
In terms of study design, the aforementioned
studies on Hcy and flow hemodynamic status were
small case–control studies.10,30 The largest previous
study had 50 participants in the control group
and 53 in the case group.10,26 Our study measured
the flow parameters and serum Hcy levels in a
total of 535 participants. The larger sample size
in our study gave it greater statistical power. The
absence of an association between Hcy concen-
trations and flow parameters was found after full
adjustment for age and sex and other vascular con-
founding factors. These results remained consistent
when Hcy was analyzed as quartile categories or
as a continuous variable. One experienced techni-
cian, who was blind to the clinical data, performed
all the duplex ultrasonography examination of
all the participants in the study, without the bias
of inter-observer reliability.
The possible reasons why our results were dif-
ferent from those in previous studies are as follows.
First, the study target populations differ between
Table 2. Hemodynamic parameter values of the carotid and vertebral arteries according to homocysteine
quartiles
Quartiles of homocysteine*
Q1 Q2 Q3 Q4
p
Common carotid artery
Systolic velocity (cm/sec) 82.52 79.84 82.93 78.63 0.250
Diastolic velocity (cm/sec) 26.48 25.62 25.02 24.55 0.020
Resistance index 0.67 0.67 0.69 0.68 0.050
Pulsatility index 1.34 1.37 1.47 1.42 0.020
Internal carotid artery
Systolic velocity (cm/sec) 66.76 63.05 64.53 60.78 0.010
Diastolic velocity (cm/sec) 31.00 29.33 29.53 27.91 0.006
Resistance index 0.53 0.53 0.54 0.53 0.770
Pulsatility index 0.81 0.82 0.86 0.83 0.770
External carotid artery
Systolic velocity (cm/sec) 70.09 68.35 71.81 71.92 0.260
Diastolic velocity (cm/sec) 14.12 14.76 15.03 14.68 0.350
Resistance index 0.79 0.78 0.79 0.79 0.990
Pulsatility index 1.95 1.89 1.98 1.99 0.240
Vertebral artery
Systolic velocity (cm/sec) 44.40 40.50 38.80 35.90 < 0.001
Diastolic velocity (cm/sec) 17.60 16.40 16.20 15.30 0.190
Resistance index 0.57 0.52 0.51 0.47 0.004
Pulsatility index 0.94 0.87 0.85 0.79 0.012
Flow volume (cm3/sec) 100.90 98.40 96.40 88.70 0.130
*Homocysteine quartiles: Q1, 1.91–7.36mmol/L; Q2, 7.37–9.07mmol/L; Q3, 9.08–11.32mmol/L; and Q4, 11.33–58.7mmol/L.
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Table 3. Adjusted mean values of flow parameters of the carotid and vertebral arteries across homocysteine
quartiles
Quartiles of Quartiles of 
Parameters homocysteine* – Model 1
†
p homocysteine* – Model 2
‡
p
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Common carotid artery
Systolic velocity (cm/sec) 81.74 79.41 82.00 81.20 0.92 79.32 77.58 80.02 79.85 0.03
Diastolic velocity (cm/sec) 25.43 25.30 25.21 25.90 0.51 25.55 25.10 25.36 26.06 0.48
Resistance index 0.68 0.68 0.69 0.68 0.70 0.67 0.67 0.68 0.67 0.74
Pulsatility index 1.39 1.38 1.43 1.39 0.93 1.33 1.36 1.39 1.34 0.96
Internal carotid artery
Systolic velocity (cm/sec) 65.11 62.60 65.18 62.44 0.39 64.15 60.09 65.58 60.56 0.39
Diastolic velocity (cm/sec) 29.82 28.99 29.87 29.18 0.71 29.99 28.37 30.50 29.19 0.83
Resistance index 0.54 0.53 0.54 0.53 0.19 0.53 0.53 0.53 0.52 0.24
Pulsatility index 0.83 0.83 0.86 0.81 0.42 0.80 0.80 0.83 0.78 0.57
Vertebral artery
Systolic velocity (cm/sec) 41.1 38.7 39.5 40.2 0.72 37.4 35.3 37.5 38.8 0.35
Diastolic velocity (cm/sec) 16.1 15.6 16.5 17.3 0.17 14.9 14.5 16.2 17.4 0.04
Resistance index 0.53 0.50 0.52 0.51 0.48 0.49 0.47 0.48 0.49 0.82
Pulsatility index 0.89 0.84 0.86 0.86 0.53 0.80 0.77 0.80 0.80 0.81
Flow volume (cm3/sec) 92.8 94.1 98.2 99.4 0.12 87.7 90.9 94.6 97.0 0.13
*Homocysteine quartiles: Q1, 1.91–7.36mmol/L; Q2, 7.37–9.07mmol/L; Q3, 9.08–11.32mmol/L; and Q4, 11.33–58.7mmol/L; †model 1: 
adjusted for age and sex; ‡model 2: model 1 plus current smoking, systolic blood pressure, serum creatinine, body mass index, uric acid, and
high-density lipoprotein.
the studies. Participants in previous studies were
selected from those who were suspected to have
coronary artery disease, whereas our study subjects
were free from symptoms of vascular diseases. Com-
pared with our asymptomatic population, people
with coronary symptoms might have different life
style, risk factors, and medication, which could
change the Hcy-related effects on blood flow.
The effects of Hcy in different categories of pop-
ulation might not be the same. The present study
of symptom-free subjects might not be applicable
entirely to diseased individuals. Second, measure-
ment of flow velocity in the extracranial cerebral
arteries in the present study and coronary artery in
other studies was different. The coronary flow was
earlier measured by angiography,10,26–28,31 whereas
carotid or vertebral artery flow in our study was
measured by duplex ultrasonography. The absolute
values of flow velocity might differ with various
methods of measurement, and that possibly ac-
counted for the difference between the results in
the present and previous studies. Compared with
ultrasonography, angiography might underesti-
mate the presence of atherosclerotic plaques.10
Besides, flow volume and flow resistance could
not have been measured in the previous coro-
nary artery studies. Intravascular ultrasonography,
which could overcome this limitation, was not
performed in these studies.10,26–28,31 Our study in-
volving ultrasonography provided more precise
hemodynamic data than did the previous studies.
Another possible explanation for our different
results is that our target vessels were the arteries
to the brain, and not the heart. The hemodynamic
patterns of the cerebral and cardiac vessels are
different because of their different physiological
mechanisms.15 The flow patterns on duplex ul-
trasonography of the peripheral vessels, including
the cardiac arteries, are triphasic waveforms with
high resistance, whereas the carotid and verte-
bral arteries show low resistance flow, to provide
adequate blood supply to the brain, and the brain
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has richer collateral circulation than any other
organ.15 Besides, the blood flow in the brain is
more constant than in the heart among healthy
individuals. This is because the brain autoregu-
latory system can prevent syncope while blood
pressure fluctuates during daily living.32 This is
possibly because the different collateral circulation
and hemodynamic status of the brain and heart
cause different effects of Hcy on the blood flow.
Therefore, clinically, the effects of Hcy on cardiac
and cerebral vascular disease might not be the
same.33,34
The study limitations are as follows. First, our
study lacked information on some determinants
of total Hcy levels, such as dietary patterns, food
folic acid fortification, and vitamin supplements.
The use of a single Hcy measurement to classify
persons might have underestimated the strength of
any association, because of regression dilution.35
Second, the extracranial carotid and vertebral ar-
teries that we sampled might not indicate com-
pletely the hemodynamic status of the intracranial
cerebral blood flow. The results of our study might
not be extrapolated entirely to the whole brain
circulation. Using transcranial Doppler sonogra-
phy could be a better way for assessing cerebral
hemodynamics. However, a poor ultrasound win-
dow with failure of penetration through the skull
is not uncommon in older people. Third, the
flow volume of the CCA and ICA was not mea-
sured according to the protocol for carotid du-
plex ultrasonography for participants undergoing
a physical health check-up. Thus, as for the carotid
artery, we could only examine the relationship of
Hcy and flow velocity. Besides, carotid or verte-
bral artery stenosis with plaques can lead to a
change in hemodynamic status. In the present
study, we could not perform subgroup analysis
on the flow parameters of the sampled arteries
with and without stenosis or plaques. Further-
more, the flow volume and velocity might have
been reduced by VA hypoplasia. We could not
clearly distinguish whether the VA was stenotic
or hypoplastic.
Table 4. Relations of plasma homocysteine to the flow parameters of the carotid and vertebral arteries
Regression Regression 
Parameters coefficients* – Model 1† p coefficients* – Model 2‡ p
(95% CI) (95% CI)
Common carotid artery
Systolic velocity (cm/sec) −0.12 (−1.52 to 1.28) 0.87 −0.92 (−2.90 to 1.04) 0.36
Diastolic velocity (cm/sec) 0.04 (−0.45 to 0.52) 0.89 0.02 (−0.68 to 0.71) 0.96
Resistance index −0.0003 (−0.006 to 0.005) 0.91 −0.003 (−0.010 to 0.004) 0.40
Pulsatility index 0.006 (−0.02 to 0.03) 0.66 −0.009 (−0.05 to 0.68) 0.61
Internal carotid artery
Systolic velocity (cm/sec) −1.15 (−2.66 to 0.37) 0.14 −1.42 (−3.52 to 0.67) 0.18
Diastolic velocity (cm/sec) −0.42 (−1.12 to 0.29) 0.24 −0.35 (−1.38 to 0.68) 0.50
Resistance index −0.002(−0.008 to 0.003) 0.46 −0.005 (−0.013 to 0.002) 0.17
Pulsatility index −0.001 (−0.017 to 0.015) 0.90 −0.007 (−0.029 to 0.015) 0.52
Vertebral artery
Systolic velocity (cm/sec) 0.24 (−1.00 to 1.50) 0.71 0.89 (−0.88 to 2.67) 0.32
Diastolic velocity (cm/sec) 0.35 (−0.31 to 1.02) 0.29 0.82 (−0.18 to 1.82) 0.11
Resistance index 0.0005 (−0.02 to 0.02) 0.95 0.002 (−0.02 to 0.02) 0.89
Pulsatility index 0.003 (−0.03 to 0.03) 0.83 0.0005 (−0.04 to 0.04) 0.98
Flow volume (cm3/sec) 2.3 (−1.06 to 5.69) 0.18 3.8 (−0.95 to 8.62) 0.12
*Linear regression coefficients represent difference of hemodynamic parameters of the carotid artery for one standard deviation incre-
ment of plasma homocysteine; †model 1: adjusted for age and sex; ‡model 2: model 1 plus current smoking, systolic blood pressure,
serum creatinine, body mass index, uric acid, and high-density lipoprotein. CI = confidence interval.
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In conclusion, we found that the flow velocity,
volume and resistance of the extracranial cerebral
arteries were not associated significantly with the
serum concentration of Hcy in asymptomatic 
individuals. This differs from the effects of Hcy on
coronary flow. Further prospective studies inves-
tigating the intracranial cerebral arteries in dis-
eased individuals are needed to confirm the role
of Hcy in the hemodynamic flow of the brain.
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